SACUBITRIL AND VALSARTAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sacubitril And Valsartan, and when can generic versions of Sacubitril And Valsartan launch?
Sacubitril And Valsartan is a drug marketed by Alembic, Alkem Labs Ltd, Biocon Pharma, Crystal, Laurus, MSN, Torrent, and Zydus Pharms. and is included in eight NDAs.
The generic ingredient in SACUBITRIL AND VALSARTAN is sacubitril; valsartan. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the sacubitril; valsartan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sacubitril And Valsartan
A generic version of SACUBITRIL AND VALSARTAN was approved as sacubitril; valsartan by ALEMBIC on May 28th, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SACUBITRIL AND VALSARTAN?
- What are the global sales for SACUBITRIL AND VALSARTAN?
- What is Average Wholesale Price for SACUBITRIL AND VALSARTAN?
Summary for SACUBITRIL AND VALSARTAN
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 8 |
| Finished Product Suppliers / Packagers: | 3 |
| Clinical Trials: | 91 |
| DailyMed Link: | SACUBITRIL AND VALSARTAN at DailyMed |
Recent Clinical Trials for SACUBITRIL AND VALSARTAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Dr. Reddy's Laboratories (Thailand) Limited | Phase 1 |
| Unidade de Investigação e Desenvolvimento Cardiovascular (UnIC) | Phase 4 |
| Rede de Investigação em Saúde | Phase 4 |
Pharmacology for SACUBITRIL AND VALSARTAN
| Drug Class | Angiotensin 2 Receptor Blocker Neprilysin Inhibitor |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists Neprilysin Inhibitors |
US Patents and Regulatory Information for SACUBITRIL AND VALSARTAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic | SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213682-001 | May 28, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Msn | SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213748-003 | Jul 24, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213719-003 | Jul 9, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Biocon Pharma | SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213680-001 | Aug 30, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Alkem Labs Ltd | SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213764-001 | Sep 16, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Crystal | SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213605-003 | May 28, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
